Botulinum toxin type a reduces hyperalgesia and TRPV1 expression in rats with neuropathic pain

Lizu Xiao, Jianguo Cheng, Yu Zhuang, Wenchun Qu, Jeffery Muir, Haowen Liang, Deren Zhang

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Objective: We aim to determine the effects of botulinum toxin type A (BTX-A) on the thresholds of pain and the expression of transient receptor potential vanilloid type 1 (TRPV1) in the dorsal root ganglion (DRG) in rats with neuropathic pain induced by selective ventral root transection (VRT). Methods: Neuropathic pain was induced by transection of the lumbar 5 ventral root in male Sprague-Dawley rats. BTX-A or saline was administered to the plantar surface by subcutaneous injection. SB366791 (an inhibitor of TRPV1) was administered intraperitoneally. Behavioral tests were conducted preoperatively and at predefined postoperative days. The expression of TRPV1 was detected and quantified by immunohistochemistry and Western blotting at postoperative days 3, 7, 14, and 21. Results.: TRPV1 expression increased significantly in the L4 ∼5 dorsal root ganglia 7 days after L5 VRT compared with the sham-operated control (P<0.05). This increase persisted for at least 21 days. The thresholds of foot withdrawal to mechanical and thermal stimulation decreased significantly as well. Subcutaneous injection of BTX-A significantly and dose-dependently reduced the expression of TRPV1 (P<0.05) and partially reversed the pain thresholds. Conclusion: Upregulation of TRPV1 expression in the DRG is an important mechanism of neuropathic pain induced by the VRT. The analgesic effect of BTX-A is most likely mediated through reduction of TRPV1 expression in the nociceptors. Wiley Periodicals, Inc.

Original languageEnglish (US)
Pages (from-to)276-286
Number of pages11
JournalPain Medicine (United States)
Volume14
Issue number2
DOIs
StatePublished - Jan 1 2013

Fingerprint

Botulinum Toxins
Hyperalgesia
Neuralgia
Type A Botulinum Toxins
Spinal Nerve Roots
Spinal Ganglia
Pain Threshold
Subcutaneous Injections
Nociceptors
vanilloid receptor subtype 1
Sprague Dawley Rats
Analgesics
Foot
Up-Regulation
Hot Temperature
Western Blotting
Immunohistochemistry

Keywords

  • Botulinum Toxin Type A (BTX-A)
  • Hyperalgesia
  • Lumbar 5 Ventral Root Transection
  • Neuropathic Pain
  • Transient Receptor Potential Vanilloid Type 1 (TRPV1)

ASJC Scopus subject areas

  • Clinical Neurology
  • Anesthesiology and Pain Medicine

Cite this

Botulinum toxin type a reduces hyperalgesia and TRPV1 expression in rats with neuropathic pain. / Xiao, Lizu; Cheng, Jianguo; Zhuang, Yu; Qu, Wenchun; Muir, Jeffery; Liang, Haowen; Zhang, Deren.

In: Pain Medicine (United States), Vol. 14, No. 2, 01.01.2013, p. 276-286.

Research output: Contribution to journalArticle

Xiao, Lizu ; Cheng, Jianguo ; Zhuang, Yu ; Qu, Wenchun ; Muir, Jeffery ; Liang, Haowen ; Zhang, Deren. / Botulinum toxin type a reduces hyperalgesia and TRPV1 expression in rats with neuropathic pain. In: Pain Medicine (United States). 2013 ; Vol. 14, No. 2. pp. 276-286.
@article{7455d316defb458b8f02b1991aa241a9,
title = "Botulinum toxin type a reduces hyperalgesia and TRPV1 expression in rats with neuropathic pain",
abstract = "Objective: We aim to determine the effects of botulinum toxin type A (BTX-A) on the thresholds of pain and the expression of transient receptor potential vanilloid type 1 (TRPV1) in the dorsal root ganglion (DRG) in rats with neuropathic pain induced by selective ventral root transection (VRT). Methods: Neuropathic pain was induced by transection of the lumbar 5 ventral root in male Sprague-Dawley rats. BTX-A or saline was administered to the plantar surface by subcutaneous injection. SB366791 (an inhibitor of TRPV1) was administered intraperitoneally. Behavioral tests were conducted preoperatively and at predefined postoperative days. The expression of TRPV1 was detected and quantified by immunohistochemistry and Western blotting at postoperative days 3, 7, 14, and 21. Results.: TRPV1 expression increased significantly in the L4 ∼5 dorsal root ganglia 7 days after L5 VRT compared with the sham-operated control (P<0.05). This increase persisted for at least 21 days. The thresholds of foot withdrawal to mechanical and thermal stimulation decreased significantly as well. Subcutaneous injection of BTX-A significantly and dose-dependently reduced the expression of TRPV1 (P<0.05) and partially reversed the pain thresholds. Conclusion: Upregulation of TRPV1 expression in the DRG is an important mechanism of neuropathic pain induced by the VRT. The analgesic effect of BTX-A is most likely mediated through reduction of TRPV1 expression in the nociceptors. Wiley Periodicals, Inc.",
keywords = "Botulinum Toxin Type A (BTX-A), Hyperalgesia, Lumbar 5 Ventral Root Transection, Neuropathic Pain, Transient Receptor Potential Vanilloid Type 1 (TRPV1)",
author = "Lizu Xiao and Jianguo Cheng and Yu Zhuang and Wenchun Qu and Jeffery Muir and Haowen Liang and Deren Zhang",
year = "2013",
month = "1",
day = "1",
doi = "10.1111/pme.12017",
language = "English (US)",
volume = "14",
pages = "276--286",
journal = "Pain Medicine",
issn = "1526-2375",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Botulinum toxin type a reduces hyperalgesia and TRPV1 expression in rats with neuropathic pain

AU - Xiao, Lizu

AU - Cheng, Jianguo

AU - Zhuang, Yu

AU - Qu, Wenchun

AU - Muir, Jeffery

AU - Liang, Haowen

AU - Zhang, Deren

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Objective: We aim to determine the effects of botulinum toxin type A (BTX-A) on the thresholds of pain and the expression of transient receptor potential vanilloid type 1 (TRPV1) in the dorsal root ganglion (DRG) in rats with neuropathic pain induced by selective ventral root transection (VRT). Methods: Neuropathic pain was induced by transection of the lumbar 5 ventral root in male Sprague-Dawley rats. BTX-A or saline was administered to the plantar surface by subcutaneous injection. SB366791 (an inhibitor of TRPV1) was administered intraperitoneally. Behavioral tests were conducted preoperatively and at predefined postoperative days. The expression of TRPV1 was detected and quantified by immunohistochemistry and Western blotting at postoperative days 3, 7, 14, and 21. Results.: TRPV1 expression increased significantly in the L4 ∼5 dorsal root ganglia 7 days after L5 VRT compared with the sham-operated control (P<0.05). This increase persisted for at least 21 days. The thresholds of foot withdrawal to mechanical and thermal stimulation decreased significantly as well. Subcutaneous injection of BTX-A significantly and dose-dependently reduced the expression of TRPV1 (P<0.05) and partially reversed the pain thresholds. Conclusion: Upregulation of TRPV1 expression in the DRG is an important mechanism of neuropathic pain induced by the VRT. The analgesic effect of BTX-A is most likely mediated through reduction of TRPV1 expression in the nociceptors. Wiley Periodicals, Inc.

AB - Objective: We aim to determine the effects of botulinum toxin type A (BTX-A) on the thresholds of pain and the expression of transient receptor potential vanilloid type 1 (TRPV1) in the dorsal root ganglion (DRG) in rats with neuropathic pain induced by selective ventral root transection (VRT). Methods: Neuropathic pain was induced by transection of the lumbar 5 ventral root in male Sprague-Dawley rats. BTX-A or saline was administered to the plantar surface by subcutaneous injection. SB366791 (an inhibitor of TRPV1) was administered intraperitoneally. Behavioral tests were conducted preoperatively and at predefined postoperative days. The expression of TRPV1 was detected and quantified by immunohistochemistry and Western blotting at postoperative days 3, 7, 14, and 21. Results.: TRPV1 expression increased significantly in the L4 ∼5 dorsal root ganglia 7 days after L5 VRT compared with the sham-operated control (P<0.05). This increase persisted for at least 21 days. The thresholds of foot withdrawal to mechanical and thermal stimulation decreased significantly as well. Subcutaneous injection of BTX-A significantly and dose-dependently reduced the expression of TRPV1 (P<0.05) and partially reversed the pain thresholds. Conclusion: Upregulation of TRPV1 expression in the DRG is an important mechanism of neuropathic pain induced by the VRT. The analgesic effect of BTX-A is most likely mediated through reduction of TRPV1 expression in the nociceptors. Wiley Periodicals, Inc.

KW - Botulinum Toxin Type A (BTX-A)

KW - Hyperalgesia

KW - Lumbar 5 Ventral Root Transection

KW - Neuropathic Pain

KW - Transient Receptor Potential Vanilloid Type 1 (TRPV1)

UR - http://www.scopus.com/inward/record.url?scp=84874518368&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874518368&partnerID=8YFLogxK

U2 - 10.1111/pme.12017

DO - 10.1111/pme.12017

M3 - Article

C2 - 23301515

AN - SCOPUS:84874518368

VL - 14

SP - 276

EP - 286

JO - Pain Medicine

JF - Pain Medicine

SN - 1526-2375

IS - 2

ER -